PDB Short entry for 3NWW HEADER TRANSFERASE/TRANSFERASE INHIBITOR 12-JUL-10 3NWW TITLE P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED TITLE 2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 14; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: MAP KINASE 14, MAPK 14, MITOGEN-ACTIVATED PROTEIN KINASE P38 COMPND 5 ALPHA, MAP KINASE P38 ALPHA, CYTOKINE SUPPRESSIVE ANTI-INFLAMMATORY COMPND 6 DRUG-BINDING PROTEIN, CSAID-BINDING PROTEIN, CSBP, MAX-INTERACTING COMPND 7 PROTEIN 2, MAP KINASE MXI2, SAPK2A; COMPND 8 EC: 2.7.11.24; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CSBP, CSBP1, CSBP2, CSPB1, MAPK14, MXI2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID KEYWDS P38 MAP KINASE, SERINE/THREONINE-PROTEIN KINASE, TRANSFERASE, KEYWDS 2 TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.S.SACK REVDAT 4 21-FEB-24 3NWW 1 REMARK REVDAT 3 02-SEP-20 3NWW 1 KEYWDS REMARK SEQADV REVDAT 2 19-JUN-13 3NWW 1 JRNL VERSN REVDAT 1 08-SEP-10 3NWW 0 JRNL AUTH S.LIN,S.T.WROBLESKI,J.HYNES,S.PITT,R.ZHANG,Y.FAN, JRNL AUTH 2 A.M.DOWEYKO,K.F.KISH,J.S.SACK,M.F.MALLEY,S.E.KIEFER, JRNL AUTH 3 J.A.NEWITT,M.MCKINNON,J.TRZASKOS,J.C.BARRISH,J.H.DODD, JRNL AUTH 4 G.L.SCHIEVEN,K.LEFTHERIS JRNL TITL UTILIZATION OF A NITROGEN-SULFUR NONBONDING INTERACTION IN JRNL TITL 2 THE DESIGN OF NEW 2-AMINOTHIAZOL-5-YL-PYRIMIDINES AS JRNL TITL 3 P38ALPHA MAP KINASE INHIBITORS. JRNL REF BIOORG.MED.CHEM.LETT. V. 20 5864 2010 JRNL REFN ISSN 0960-894X JRNL PMID 20732813 JRNL DOI 10.1016/J.BMCL.2010.07.102 REMARK 2 REMARK 2 RESOLUTION. 2.09 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.9.3 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.09 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 22.90 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 94.4 REMARK 3 NUMBER OF REFLECTIONS : 22432 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.214 REMARK 3 R VALUE (WORKING SET) : 0.212 REMARK 3 FREE R VALUE : 0.254 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.160 REMARK 3 FREE R VALUE TEST SET COUNT : 1158 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 11 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.09 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.19 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 94.36 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2403 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2158 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2287 REMARK 3 BIN R VALUE (WORKING SET) : 0.2145 REMARK 3 BIN FREE R VALUE : 0.2436 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.83 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 116 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2741 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 34 REMARK 3 SOLVENT ATOMS : 209 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 36.97 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 40.46 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -5.77770 REMARK 3 B22 (A**2) : 7.13890 REMARK 3 B33 (A**2) : -1.36120 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.298 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : NULL REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.240 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.946 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.931 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2841 ; 2.000 ; NULL REMARK 3 BOND ANGLES : 3855 ; 2.000 ; NULL REMARK 3 TORSION ANGLES : 979 ; 2.000 ; NULL REMARK 3 TRIGONAL CARBON PLANES : 69 ; 2.000 ; NULL REMARK 3 GENERAL PLANES : 404 ; 5.000 ; NULL REMARK 3 ISOTROPIC THERMAL FACTORS : 2841 ; 20.000 ; NULL REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 364 ; 5.000 ; NULL REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 3453 ; 4.000 ; NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.09 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.05 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 19.34 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3NWW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 14-JUL-10. REMARK 100 THE DEPOSITION ID IS D_1000060380. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-JUL-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-E SUPERBRIGHT REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54180 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MICROMAX CONFOCAL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU SATURN 92 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24028 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 78.640 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 90.0 REMARK 200 DATA REDUNDANCY : 7.200 REMARK 200 R MERGE (I) : 0.05900 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 24.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.11 REMARK 200 COMPLETENESS FOR SHELL (%) : 57.5 REMARK 200 DATA REDUNDANCY IN SHELL : 6.30 REMARK 200 R MERGE FOR SHELL (I) : 0.47300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.94 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.32 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 33.07750 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.31400 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 37.52750 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.31400 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 33.07750 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 37.52750 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -5 REMARK 465 ALA A -4 REMARK 465 HIS A -3 REMARK 465 HIS A -2 REMARK 465 HIS A -1 REMARK 465 HIS A 0 REMARK 465 HIS A 1 REMARK 465 SER A 2 REMARK 465 GLN A 3 REMARK 465 GLU A 4 REMARK 465 THR A 175 REMARK 465 ASP A 176 REMARK 465 ASP A 177 REMARK 465 GLU A 178 REMARK 465 MET A 179 REMARK 465 THR A 180 REMARK 465 GLY A 181 REMARK 465 TYR A 182 REMARK 465 VAL A 183 REMARK 465 ALA A 184 REMARK 465 ASP A 354 REMARK 465 GLN A 355 REMARK 465 GLU A 356 REMARK 465 GLU A 357 REMARK 465 MET A 358 REMARK 465 GLU A 359 REMARK 465 SER A 360 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 15 -4.95 67.53 REMARK 500 TYR A 35 32.25 70.08 REMARK 500 PHE A 99 107.14 -56.06 REMARK 500 ASN A 100 -5.47 -143.51 REMARK 500 GLN A 120 -83.59 -150.19 REMARK 500 ARG A 149 -20.29 77.98 REMARK 500 TRP A 197 -77.05 -69.29 REMARK 500 TYR A 200 140.92 67.20 REMARK 500 PHE A 274 51.87 -97.36 REMARK 500 LEU A 289 41.35 -96.23 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 3NW A 361 DBREF 3NWW A 2 360 UNP Q16539 MK14_HUMAN 2 360 SEQADV 3NWW MET A -5 UNP Q16539 EXPRESSION TAG SEQADV 3NWW ALA A -4 UNP Q16539 EXPRESSION TAG SEQADV 3NWW HIS A -3 UNP Q16539 EXPRESSION TAG SEQADV 3NWW HIS A -2 UNP Q16539 EXPRESSION TAG SEQADV 3NWW HIS A -1 UNP Q16539 EXPRESSION TAG SEQADV 3NWW HIS A 0 UNP Q16539 EXPRESSION TAG SEQADV 3NWW HIS A 1 UNP Q16539 EXPRESSION TAG SEQRES 1 A 366 MET ALA HIS HIS HIS HIS HIS SER GLN GLU ARG PRO THR SEQRES 2 A 366 PHE TYR ARG GLN GLU LEU ASN LYS THR ILE TRP GLU VAL SEQRES 3 A 366 PRO GLU ARG TYR GLN ASN LEU SER PRO VAL GLY SER GLY SEQRES 4 A 366 ALA TYR GLY SER VAL CYS ALA ALA PHE ASP THR LYS THR SEQRES 5 A 366 GLY LEU ARG VAL ALA VAL LYS LYS LEU SER ARG PRO PHE SEQRES 6 A 366 GLN SER ILE ILE HIS ALA LYS ARG THR TYR ARG GLU LEU SEQRES 7 A 366 ARG LEU LEU LYS HIS MET LYS HIS GLU ASN VAL ILE GLY SEQRES 8 A 366 LEU LEU ASP VAL PHE THR PRO ALA ARG SER LEU GLU GLU SEQRES 9 A 366 PHE ASN ASP VAL TYR LEU VAL THR HIS LEU MET GLY ALA SEQRES 10 A 366 ASP LEU ASN ASN ILE VAL LYS CYS GLN LYS LEU THR ASP SEQRES 11 A 366 ASP HIS VAL GLN PHE LEU ILE TYR GLN ILE LEU ARG GLY SEQRES 12 A 366 LEU LYS TYR ILE HIS SER ALA ASP ILE ILE HIS ARG ASP SEQRES 13 A 366 LEU LYS PRO SER ASN LEU ALA VAL ASN GLU ASP CYS GLU SEQRES 14 A 366 LEU LYS ILE LEU ASP PHE GLY LEU ALA ARG HIS THR ASP SEQRES 15 A 366 ASP GLU MET THR GLY TYR VAL ALA THR ARG TRP TYR ARG SEQRES 16 A 366 ALA PRO GLU ILE MET LEU ASN TRP MET HIS TYR ASN GLN SEQRES 17 A 366 THR VAL ASP ILE TRP SER VAL GLY CYS ILE MET ALA GLU SEQRES 18 A 366 LEU LEU THR GLY ARG THR LEU PHE PRO GLY THR ASP HIS SEQRES 19 A 366 ILE ASP GLN LEU LYS LEU ILE LEU ARG LEU VAL GLY THR SEQRES 20 A 366 PRO GLY ALA GLU LEU LEU LYS LYS ILE SER SER GLU SER SEQRES 21 A 366 ALA ARG ASN TYR ILE GLN SER LEU THR GLN MET PRO LYS SEQRES 22 A 366 MET ASN PHE ALA ASN VAL PHE ILE GLY ALA ASN PRO LEU SEQRES 23 A 366 ALA VAL ASP LEU LEU GLU LYS MET LEU VAL LEU ASP SER SEQRES 24 A 366 ASP LYS ARG ILE THR ALA ALA GLN ALA LEU ALA HIS ALA SEQRES 25 A 366 TYR PHE ALA GLN TYR HIS ASP PRO ASP ASP GLU PRO VAL SEQRES 26 A 366 ALA ASP PRO TYR ASP GLN SER PHE GLU SER ARG ASP LEU SEQRES 27 A 366 LEU ILE ASP GLU TRP LYS SER LEU THR TYR ASP GLU VAL SEQRES 28 A 366 ILE SER PHE VAL PRO PRO PRO LEU ASP GLN GLU GLU MET SEQRES 29 A 366 GLU SER HET 3NW A 361 34 HETNAM 3NW 1-[2-(2-{[2-(DIMETHYLAMINO)ETHYL]AMINO}-6-{2-[(1- HETNAM 2 3NW METHYLETHYL)AMINO]-1,3-THIAZOL-5-YL}PYRIMIDIN-4-YL) HETNAM 3 3NW BENZYL]-3-ETHYLUREA FORMUL 2 3NW C24 H34 N8 O S FORMUL 3 HOH *209(H2 O) HELIX 1 1 SER A 61 MET A 78 1 18 HELIX 2 2 LEU A 113 VAL A 117 1 5 HELIX 3 3 THR A 123 ALA A 144 1 22 HELIX 4 4 LYS A 152 SER A 154 5 3 HELIX 5 5 THR A 185 ARG A 189 5 5 HELIX 6 6 ALA A 190 ASN A 196 1 7 HELIX 7 7 THR A 203 GLY A 219 1 17 HELIX 8 8 ASP A 227 GLY A 240 1 14 HELIX 9 9 GLY A 243 LYS A 248 1 6 HELIX 10 10 SER A 252 LEU A 262 1 11 HELIX 11 11 ASN A 269 VAL A 273 5 5 HELIX 12 12 ASN A 278 LEU A 289 1 12 HELIX 13 13 THR A 298 ALA A 304 1 7 HELIX 14 14 HIS A 305 ALA A 309 5 5 HELIX 15 15 GLN A 325 ARG A 330 5 6 HELIX 16 16 LEU A 333 SER A 347 1 15 SHEET 1 A 2 PHE A 8 LEU A 13 0 SHEET 2 A 2 THR A 16 PRO A 21 -1 O THR A 16 N LEU A 13 SHEET 1 B 5 TYR A 24 GLY A 33 0 SHEET 2 B 5 GLY A 36 ASP A 43 -1 O GLY A 36 N GLY A 33 SHEET 3 B 5 ARG A 49 LEU A 55 -1 O VAL A 52 N CYS A 39 SHEET 4 B 5 TYR A 103 HIS A 107 -1 O LEU A 104 N LYS A 53 SHEET 5 B 5 ASP A 88 PHE A 90 -1 N ASP A 88 O VAL A 105 SHEET 1 C 3 ALA A 111 ASP A 112 0 SHEET 2 C 3 LEU A 156 VAL A 158 -1 O VAL A 158 N ALA A 111 SHEET 3 C 3 LEU A 164 ILE A 166 -1 O LYS A 165 N ALA A 157 CISPEP 1 CYS A 119 GLN A 120 0 -3.96 SITE 1 AC1 20 SER A 32 GLY A 33 ALA A 34 ALA A 51 SITE 2 AC1 20 GLU A 71 LEU A 74 LEU A 75 LEU A 104 SITE 3 AC1 20 THR A 106 HIS A 107 MET A 109 GLY A 110 SITE 4 AC1 20 ALA A 111 SER A 154 LEU A 167 ASP A 168 SITE 5 AC1 20 PHE A 169 HOH A 399 HOH A 418 HOH A 527 CRYST1 66.155 75.055 78.628 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015116 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013324 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012718 0.00000